Nielsen S E, Munch-Petersen B, Mejer J
Department of Hematology and Oncology, Roskilde Hospital, Denmark.
Leuk Res. 1995 Jul;19(7):443-7. doi: 10.1016/0145-2126(94)00153-2.
Deoxycytidine kinase (dCK) is important in the 5'-phosphorylation of deoxynucleoside analogs. Like dCK, thymidine kinase 2 (TK2) catalyzes the initial step of the phosphorylation of dcyd to dCTP. Thymidine is a strong inhibitor of the dCK activity of TK2. We examined the ratio of the dcyd phosphorylation carried out by dCK and by TK2 (dCK/TK2-dcyd) in lymphocytes from CLL patients and from donors. In the CLL lymphocytes we found a 3.5-fold average increase. Therefore, we conclude that addition of thymidine in the treatment of CLL with deoxynucleoside analogs will not be of any advantage. Furthermore, our results can explain earlier findings in CML and AML lymphocytes where the ara-C phosphorylation was twice the dcyd phosphorylation.
脱氧胞苷激酶（dCK）在脱氧核苷类似物的5'-磷酸化过程中起着重要作用。与dCK一样，胸苷激酶2（TK2）催化脱氧胞苷磷酸化为dCTP的第一步反应。胸苷是TK2的dCK活性的强效抑制剂。我们检测了慢性淋巴细胞白血病（CLL）患者和供体淋巴细胞中由dCK和TK2进行的脱氧胞苷磷酸化比例（dCK/TK2-脱氧胞苷）。在CLL淋巴细胞中，我们发现平均增加了3.5倍。因此，我们得出结论，在用脱氧核苷类似物治疗CLL时添加胸苷不会带来任何益处。此外，我们的结果可以解释先前在慢性粒细胞白血病（CML）和急性髓细胞白血病（AML）淋巴细胞中的发现，其中阿糖胞苷（ara-C）的磷酸化是脱氧胞苷磷酸化的两倍。
